Navigation Links
Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics

Latest awards under Therapeutics Development Initiative bring MJFF's current active industry collaborations to 23; next deadline January 20, 2009

NEW YORK, July 22 /PRNewswire-USNewswire/ -- As part of its mission to speed delivery of transformative treatments and a cure for Parkinson's disease, The Michael J. Fox Foundation for Parkinson's Research has awarded $2.7 million in total funding to six industry research teams. The awards were granted under MJFF's Therapeutics Development Initiative (TDI) program. Open exclusively to researchers at biotech and pharmaceutical companies, TDI is the cornerstone of the Foundation's venture philanthropy efforts to spark and expand industry investment in PD drug development. In an increasingly risk-averse research funding climate, TDI helps to push promising candidate therapeutics forward in industry pipelines by allowing the Foundation to share the risk of drug development.

"At MJFF, our job is to do whatever it takes to speed therapeutics development for Parkinson's disease," said Katie Hood, CEO of The Michael J. Fox Foundation. "Early on we realized the critical importance of forging financial and intellectual partnerships with industry as well as academic research teams. Our private philanthropy dollars -- raised largely from patients themselves -- have a critical role to play in 'de-risking' therapeutic targets for industry investment in order to keep the most promising ideas moving forward toward clinical testing and pharmacy shelves."

Funded projects focus on:

-- Developing a vaccine that could protect against toxicity of the PD-implicated protein alpha-synuclein (Ingeborg Muehldorfer, Ph.D., Rentschler Biotechnologie, Laupheim, Germany);

-- Improving delivery of the gold-standard Parkinson's treatment, levodopa, which could lessen debilitating side effects of the drug including dyskinesias, the uncontrollable movements that arise with long-term levodopa therapy (Verne Cowles, Ph.D., and S. Y. Eddie Hou, Ph.D., Depomed, Inc., Menlo Park, California);

-- Validating a novel metabolomic diagnostic test for PD (Hyman Schipper, MD, PhD, FRCPC, and Peter Roos, Ph.D., Molecular Biometrics, Montreal, Canada);

-- Finding new ways to target the PD-implicated gene LRRK2 (Vicki Nienaber, Ph.D., Zenobia Therapeutics, San Diego, California);

-- Investigating methods to modulate the new PD target GPR88, a protein receptor believed to play a role in dopaminergic function (Thomas Sager, Ph.D., and Kenneth Thirstrup, Ph.D., H. Lundbeck A/S, Valby, Denmark); and

-- Exploring gene-knockout techniques to protect against oxidative stress implicated in the neuronal loss that characterizes PD (Kenneth Thirstrup, PhD, and Thomas Sager, Ph.D., H. Lundbeck A/S, Valby, Denmark).

Detailed grant abstracts and researchers' bios are available at

While The Michael J. Fox Foundation has funded industry research teams since its inception, it launched the Therapeutics Development Initiative in 2006 as part of a proactive initiative to capture the attention and imagination of for-profit decision-makers and encourage them to allocate resources to Parkinson's drug development. In 2007, recognizing the increasing sophistication of many university drug development programs, the Foundation added a one-time-only "academic track" to fund non-industry-based teams working toward transformative PD treatments. The Foundation has committed about $24 million in total funding to industry to date. Slightly less than half of that total (over $10 million) has gone to the 20 projects funded through the Therapeutics Development Initiative thus far.

The deadline for pre-proposals under the next $2.5-million, industry-only funding round of TDI is January 20, 2009. The program will again seek to support preclinical development of Parkinson's disease therapies with potential to fundamentally alter disease course and/or improve treatment of symptoms above and beyond current standards of care. Proposals must focus on key and critical preclinical studies necessary for developing, optimizing and evaluating therapeutic strategies that if successful can move into human testing. Full information for prospective applicants is available at

About The Michael J. Fox Foundation

Founded in 2000, The Michael J. Fox Foundation for Parkinson's Research is dedicated to ensuring the development of a cure for Parkinson's disease within the coming decade through an aggressively funded research agenda. The Foundation has funded approximately $126 million in research to date.

SOURCE Michael J. Fox Foundation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Michael J. Fox Foundation Awards $2.4 Million for Validation of Nine Promising Therapeutic Targets for Parkinsons Disease
2. The Foundation for Biomedical Research Announces Winners of the 7th Annual Michael E. DeBakey Journalism Awards
3. Michael J. Fox Foundation Announces $5.6-Million Award for Phase 2 Clinical Trial Studying Neuroprotective Potential of Inosine
4. Michael J. Fox Foundation Commits up to $10 Million for Pre-Clinical Drug Development Under Therapeutics Development Initiative
5. New Michael J. Fox Foundation Initiative Will Drive Development of Web-Based Tools to Increase Patient Participation in Parkinsons Clinical Trials
6. Michael J. Fox Foundation Commits Up to $3 Million for Clinical Trials That Can Improve Treatment of Parkinsons Disease
7. Michael J. Fox Foundation Awards Up to $3 Million to Industry Teams to Jumpstart Promising PD Drug Development
8. PTC Therapeutics Announces $25 Million Award From Cystic Fibrosis Foundation Therapeutics for Development of PTC124
9. Childrens Brain Tumor Foundations Tissue Bank Consortium May Solve Dire Problem in Pediatric Cancer Research
10. Canopus BioPharma Strengthens its CB1400 Platform Technology for Mucositis and Oncology Treatments Through License Agreement With Wisconsin Alumni Research Foundation
11. Quantum Immunologics, Inc. and the South Alabama Medical Science Foundation Announce an Early Clinical Evaluation of a Novel Immuno-therapeutic Vaccine for Treating Advanced Human Breast Carcinomas
Post Your Comments:
(Date:11/24/2015)... Avery Biomedical Devices (ABD), manufacturer of the ... appointment of Anders Jonzon , MD; Ph.D. as ... Dr. Jonzon is a Physiologist and consultant ... University, Uppsala and Children,s Hospital, Karolinska, Stockholm, ... at the Cardiovascular Institute (UCSF). His research has covered ...
(Date:11/24/2015)... LAUSANNE and BERN, Switzerland ... SA, the ARTORG Center for Biomedical Engineering Research of ... and the Division of Endocrinology, Diabetes and Clinical Nutrition ... announce the start of an exclusive collaboration to develop ... control algorithm for the personalised delivery of insulin for ...
(Date:11/24/2015)... Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that ... Education and Human Resources will be presenting in the upcoming ... Plan Strategies for a Dynamic Market" on Dec. 1, 2015. ... consultant with the Cambridge Advisory Group, where she leads their ... The webinar will discuss the rapid growth of oral oncolytics, ...
Breaking Medicine Technology:
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... Dr. Rodney E. Willey , has ... new venture, Koala Center for Sleep Disorders, provides treatment for snoring and sleep apnea ... have opened a Koala Center for Sleep Disorders in the US, one of four in ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... and Healthy Aging Program have announced their endorsement of the Medical Fitness ... Health Fitness is proud to have the MFN as one of our endorsed ...
(Date:11/24/2015)... , ... November 24, 2015 , ... Autism Speaks, the ... global movement driven by social media and the generosity of people around the world. ... their social media networks to give – and share the personal stories behind those ...
(Date:11/24/2015)... Miami, FL (PRWEB) , ... November 24, 2015 ... ... manufacturer and engineer of patented products, announces Innovative Blending, a household invention that ... go. , "The Juice & Smoothie Bars market is worth $2 billion," says ...
(Date:11/24/2015)... ... November 24, 2015 , ... Robert Yeager CEO of PharmMD, has ... past year there have been multiple breakthroughs and challenges as healthcare reform moves out ... enabled their customers and partners to stay ahead of the curve by breaking down ...
Breaking Medicine News(10 mins):